Journal
PLOS ONE
Volume 16, Issue 1, Pages -Publisher
PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0245024
Keywords
-
Categories
Funding
- Battelle Memorial Institute
- US National Institute of Allergy and Infectious Diseases (NIAID) [HHSN272200700016I]
- Laulima Government Solutions, LLC
- NIAID [HHSN272201800013C]
- Laulima Government Solutions, LLC [HHSN272201800013C]
- Division of Intramural Research of NIAID [ZIA AI000538-30]
Ask authors/readers for more resources
The immunotoxin 6D8-PE38 specifically targets Ebola virus-infected cells and effectively inhibits viral production, showing promise as a potential antiviral intervention for Ebola virus disease.
Ebola virus (EBOV), a member of the mononegaviral family Filoviridae, causes severe disease associated with high lethality in humans. Despite enormous progress in development of EBOV medical countermeasures, no anti-EBOV treatment has been approved. We designed an immunotoxin in which a single-chain variable region fragment of the EBOV glycoprotein-specific monoclonal antibody 6D8 was fused to the effector domains of Pseudomonas aeruginosa exotoxin A (PE38). This immunotoxin, 6D8-PE38, bound specifically to cells expressing EBOV glycoproteins. Importantly, 6D8-PE38 targeted EBOV-infected cells, as evidenced by inhibition of infectious EBOV production from infected cells, including primary human macrophages. The data presented here provide a proof of concept for immunotoxin-based targeted killing of infected cells as a potential antiviral intervention for Ebola virus disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available